AATB

26 Tissue Donors Who Gave the Gift of Life and Two Tissue Recipients Whose Lives Were Transformed by the Power of Donation will Participate in the 2024 OneLegacy Donate Life Float on New Year’s Day

Retrieved on: 
Friday, December 22, 2023
Men, Other Health, General Health, Entertainment, Events, Concerts, Philanthropy, Consumer, General Entertainment, Foundation, Surgery, Women, Other Philanthropy, Health, Music, Family, Trochlea, Survivor, Running, Woman, Transplant, Pain, AATB, Burn, Patella, Tissue, Eye, The Dance of Life, Dance, Heart, Leg, Pharmaceutical industry

The two tissue recipients, along with 26 floral portraits or floragraphs of cornea and tissue donors, represent the healing and transformational power of tissue donation.

Key Points: 
  • The two tissue recipients, along with 26 floral portraits or floragraphs of cornea and tissue donors, represent the healing and transformational power of tissue donation.
  • “We are honored to co-sponsor tissue recipient Joceline Pérez Hernández on the 2024 OneLegacy Donate Life float.
  • The 2024 OneLegacy Donate Life Float tissue recipients include the following float riders:
    Joceline Perez Hernandez is a bone tissue recipient from San Bernardino.
  • The 2024 float will honor 56 participants, including 22 riders and walkers who are either living donors, or organ and tissue recipients.

Induce Biologics Announces Launch of NMP Cancellous Strips

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Surgery, Medical Devices, NMP, BMA, Surgeon, Public sector banks in India, Temperature, AATB, Blood, American Association of Tissue Banks, PRP, National Baptist Convention, USA, Inc., Phosphorus

The new product is an advanced cancellous bone-graft solution utilizing Induce Biologics’ proprietary Natural Matrix Protein (NMP) process, which unlocks the growth factors naturally found in bone, making them bioavailable.

Key Points: 
  • The new product is an advanced cancellous bone-graft solution utilizing Induce Biologics’ proprietary Natural Matrix Protein (NMP) process, which unlocks the growth factors naturally found in bone, making them bioavailable.
  • NMP Strips, the latest member of Induce Biologics’ NMP product family, feature an optimal strip design providing ideal handling characteristics for fluid retention and expansion.
  • “We are pleased to introduce this new addition to the NMP Bioimplant line,” said David Campagnari, President of Induce Biologics USA.
  • Our launch of the NMP Strip format, in addition to our existing NMP Particulates and NMP Fibers, provides surgeons with another bone-graft option, utilizing Induce Biologics’ proprietary Natural Matrix Protein (NMP) process, which unlocks the growth factors naturally found in bone, making them bioavailable.

BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing

Retrieved on: 
Wednesday, February 1, 2023
Cleveland State University, Marketing, Novartis, MBA, Krannert School of Management, Regenerative medicine, Jack Welch Management Institute, Plastic, Smith & Nephew, Purdue University, AATB, Certified Tissue Bank Specialist, Washington University in St. Louis, Covidien, Kimberly-Clark, Chemistry, Emory University, Growth, Organization, Johnson & Johnson, Biology, Elective surgery, University, Management, Science

“With strong initial success in the regenerative therapeutics space, BioStem Technologies is positioned for aggressive growth.

Key Points: 
  • “With strong initial success in the regenerative therapeutics space, BioStem Technologies is positioned for aggressive growth.
  • Mr. Sylvester has extensive experience leading sales teams and organizations in orthopedics, plastics, general, and oral/ent surgical markets.
  • “Michael’s entrepreneurial mindset and innovative solutions have driven transformational change in organizations that resulted in significant growth.
  • Jason Matuszewski continued, “with significant experience in marketing, brand and product development, Neal will serve as the commercial lead to make BioStem Technologies a well recognized, leading name in regenerative therapeutics.”

BioStem Technologies Announces Partnership with Kill Cliff FC

Retrieved on: 
Wednesday, December 14, 2022
Public sector banks in India, Physician, Champion, Allotransplantation, MMA, Health, FDA, Regenerative medicine, OTC, Injury, Ultimate, Erosion (morphology), Research, American Association of Tissue Banks, Athlete, COVID-19, AATB, Pharmaceutical industry

POMPANO BEACH, FLORIDA., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, is pleased to announce that the Company will be a corporate sponsor of Kill Cliff Fight Club (“Kill Cliff FC”), a world-renowned MMA training center based-in Southern Florida.

Key Points: 
  • Kill Cliff FC has more than 80 professional fighters including current and former Champions from the Ultimate Fighting Championship (“UFC”), Bellator MMA, One Championship, and other elite MMA promotions.
  • Under Henri Hooft and Greg Jones, Kill Cliff FC has developed and produced elite fighters such as Michael Chandler, Gilbert Burns, Robbie Lawler, Logan Storley, Aung La Nsang and Gregory Rodrigues.
  • Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “The entire team at BioStem is excited for our products to become an integral part of the MMA community.
  • Now BioStem will be associated with some of the biggest moments in MMA.”
    Greg Jones, Co-Founder of Kill Cliff FC, commented “Kill Cliff FC is truly honored to be partnering with BioStem.

REGENATIVE LABS ANNOUNCES CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN POST-SURGICAL BREAST REDUCTION

Retrieved on: 
Monday, December 12, 2022
Mammaplasty, Medical degree, Literature, Physician, Breast, Distress, Ministry of Education (Malaysia), AATB, Infection, American Academy, Patient, Mayo Clinic, Breast reduction, Hospital, Wharton's jelly, FDA, Pain, Johns Hopkins Hospital, American Board of Commissioners for Foreign Missions, Health, University, AOA, Mouth ulcer, Multimedia, Ulcer, Plastic, Structural Damage, Walter Reed Army Medical Center, Medical device, Medical imaging, Pharmaceutical industry, Labs, Regenerative medicine

PENSACOLA, Fla., Dec. 12, 2022 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces advancements in breast reduction post-surgical complication care.

Key Points: 
  • PENSACOLA, Fla., Dec. 12, 2022 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces advancements in breast reduction post-surgical complication care.
  • "With Wharton's Jelly, we were able to close a wound that would normally take 3 months, in 3 weeks," he concluded.
  • The average price of breast reduction is $7000 alone, with extra care incurring additional cost.
  • About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments.

BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call

Retrieved on: 
Tuesday, November 15, 2022
COVID-19, OTC, Allotransplantation, Public sector banks in India, Regenerative medicine, Physician, Webcast, Research, AATB, American Association of Tissue Banks, FDA, Risk management

About BioStem Technologies, Inc. (OTC PINK: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.

Key Points: 
  • About BioStem Technologies, Inc. (OTC PINK: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
  • The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method.
  • BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB").
  • Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.

BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer

Retrieved on: 
Wednesday, October 26, 2022
SEC, Company, Accounting, Private Securities Litigation Reform Act, Forward-looking statement, Rutgers University, Controller, IPO, Physician, CPA, Technology, Allotransplantation, Compliance, Regenerative medicine, Public sector banks in India, American Association of Tissue Banks, OTC, American Association, Research, COVID-19, GLOBE, Association, FDA, San Francisco Bay Area, AATB, Health, Security (finance)

Mr. Fortunato brings over 28 years of expert level financial accounting, SEC reporting, M&A and IPO experience to BioStem.

Key Points: 
  • Mr. Fortunato brings over 28 years of expert level financial accounting, SEC reporting, M&A and IPO experience to BioStem.
  • BioStem has made substantial progress and is now reaching an exciting inflection point given our strong commercial momentum, said Jason Matuszewski, Chief Executive Officer of BioStem.
  • Looking at the future of BioStem, having Michael in the role of Chief Financial Officer will help bring the company to the next level given his extensive experience in finance, accounting, and strategic execution.
  • Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.

BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Retrieved on: 
Monday, October 10, 2022
Physician, Investor relations, Allotransplantation, Research, AATB, Private Securities Litigation Reform Act, Company, American Association, Association, OTC, GLOBE, Forward-looking statement, Regenerative medicine, FDA, COVID-19, American Association of Tissue Banks, Public sector banks in India, Risk management

POMPANO BEACH, FLORIDA., Oct. 10, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC PINK: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived tissue allografts, today announced that Jason Matuszewski, Chief Executive Officer, will present at theDawson James Securities 2022 Small Cap Growth ConferenceonWednesday, October 12th, 2022.

Key Points: 
  • POMPANO BEACH, FLORIDA., Oct. 10, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC PINK: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived tissue allografts, today announced that Jason Matuszewski, Chief Executive Officer, will present at theDawson James Securities 2022 Small Cap Growth ConferenceonWednesday, October 12th, 2022.
  • BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure.
  • BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB").
  • Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.

REGENATIVE LABS RELEASES NEW STUDY DEMONSTRATING EFFICACY OF AMNIOTIC MEMBRANE ALLOGRAFT APPLICATION IN ADVANCED VENOUS LEG UCLERS

Retrieved on: 
Thursday, September 22, 2022
Algorithm, Extremities, FDA, Wharton, DAMA, Cell death, AATB, Health, Labs, Chronic venous insufficiency, Infection, Amputation, Patient, Neomycin/polymyxin B/bacitracin, Physician, Regenerative medicine, Pain, Quality of life, Cell, CVI, Bandage, Research, Hospital, Multimedia, Disease, Death, Stasis dermatitis, Pharmaceutical industry

PENSACOLA, Fla., Sept. 22, 2022 /PRNewswire/ -- Regenative Labs, a leading HCT/P manufacturer, has authored a peer-reviewed case study outlining the benefits of dehydrated amniotic membrane allografts (DAMA) in the treatment of advanced venous leg ulcers caused by chronic venous insufficiency (CVI). 

Key Points: 
  • PENSACOLA, Fla., Sept. 22, 2022 /PRNewswire/ -- Regenative Labs, a leading HCT/P manufacturer, has authored apeer-reviewed case study outlining the benefits of dehydrated amniotic membrane allografts (DAMA) in the treatment of advanced venous leg ulcers caused by chronic venous insufficiency (CVI).
  • At its core, CVI involves blood pooling in the lower extremities secondary to inadequate venous blood return.
  • As venous circulation slows, metabolic demands of the cells in the lower extremities increase, leading to stasis dermatitis, infection, cellular death, and venous ulceration.
  • Regenative's study outlines a patient case demonstrating the efficacy of DAMA application in accelerating wound closure time.